Drug Profile
Research programme: CAR-T cell therapies - Endocyte/Purdue University
Alternative Names: FITC CAR-T; SMDC Bi-specific Adaptor CAR-T cell therapyLatest Information Update: 12 Oct 2023
Price :
$50
*
At a glance
- Originator Endocyte
- Developer Endocyte; Purdue University
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 12 Oct 2023 Discontinued - Preclinical for Solid tumours in USA (Parenteral) (Novartis website, October 2023)
- 28 May 2020 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 21 Dec 2018 Endocyte has been acquired by Novartis